Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher D.M. Fletcher, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Christopher Fletcher and Annick Van Den Abbeele.
Connection Strength

0.197
  1. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
    View in: PubMed
    Score: 0.027
  2. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
    View in: PubMed
    Score: 0.024
  3. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
    View in: PubMed
    Score: 0.023
  4. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
    View in: PubMed
    Score: 0.019
  5. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
    View in: PubMed
    Score: 0.019
  6. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
    View in: PubMed
    Score: 0.019
  7. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
    View in: PubMed
    Score: 0.019
  8. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
    View in: PubMed
    Score: 0.018
  9. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
    View in: PubMed
    Score: 0.017
  10. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.